<DOC>
	<DOC>NCT03030066</DOC>
	<brief_summary>This is a study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of DS-1001b in patients with gliomas that harbor IDH1-R132 mutations.</brief_summary>
	<brief_title>Study of DS-1001b in Patients With Gene IDH1-Mutated Gliomas</brief_title>
	<detailed_description />
	<mesh_term>Glioma</mesh_term>
	<criteria>1. Has histologically confirmed glioma with an IDH1R132 mutation 2. Has disease that has recurred or progressed following standard treatment including radiotherapy 3. Has measurable lesion(s) as per RANO criteria 4. Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 1. Has significant symptoms of increased intracranial pressure 2. Has another active neoplasm 3. Has active infection requiring systemic treatment 4. Has a history of severe cardiac disease 5. Has had prior treatment with any inhibitor targeting mutant IDH1 6. Has had investigational drug treatment within 4 weeks prior to the first dose of study treatment 7. Is a pregnant or lactating female</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>DS-1001b</keyword>
	<keyword>IDH1 mutation</keyword>
	<keyword>Developmental Phase I</keyword>
	<keyword>Glioma</keyword>
</DOC>